NYSE:EBSBiotechs
Emergent BioSolutions (EBS) Is Up 6.5% After Upgraded 2025 Outlook and Strong Q3 Results Has the Bull Case Changed?
Emergent BioSolutions recently reported third-quarter 2025 results, with revenue of US$231.1 million and net income of US$51.2 million, and raised its full-year 2025 guidance for both revenue and net income.
The company's stronger-than-expected performance was supported by growth in NARCAN nasal spray, new U.S. government and international contracts, and a completed share repurchase program.
We'll now examine how the company's upgraded full-year outlook and growth in core product lines may...